Last reviewed · How we verify
AMA1
At a glance
| Generic name | AMA1 |
|---|---|
| Sponsor | African Malaria Network Trust |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults (PHASE1)
- Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)
- Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria (PHASE1, PHASE2)
- Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali (PHASE2)
- FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali (PHASE1)
- Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum (PHASE1)
- Experimental Vaccine for Malaria (PHASE1)
- Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMA1 CI brief — competitive landscape report
- AMA1 updates RSS · CI watch RSS
- African Malaria Network Trust portfolio CI